Dr James Roberts Talks about Cholrem - Cavadex

OUR RESEARCH

TREATMENT FOR ATHEROSCLEROSIS

CAVADEXTRIN® is a brand of Cyclodextrin developed by Cholrem that removes cholesterol and plaque from arteries.

Research into cyclodextrin is quickly proving cyclodextrin will emerge as one of the major therapeutical treatments of the 21st century. Scientific studies and research into cyclodextrin are showing that enhanced cholesterol transport within the body has major benefits for treating age-related conditions.

Order Now

THE CAVADEXTRIN® MOLECULE

Developed by Cholrem in 2019, the CAVADEXTRIN® molecule absorbs cholesterol from arterial plaque and transports it safely out through the urinary system.

CAVADEXTRIN® has shown to lower triglycerides by 50% and cholesterol by 40% in just 2 weeks.

CAVADEXTRIN® removes the cholesterol from your arteries.

Order Now
  • FIRST TRIAL OF CAVADEXTRIN®

    APRIL 2019

    CAVADEXTRIN® REDUCES PLAQUE WITHIN 4 WEEKS

    CAVADEXTRIN® was administered to our first patient in our Melbourne clinic in April 2019 and within 4 weeks the plaque was reduced.

    CAVADEXTRIN® circulates around the cardiovascular system removing built up cholesterol and plaque resulting in significant plaque reduction.


    CAVADEXTRIN® is absorbed via intravenous application or as an enema only. If taken orally it is destroyed in the gut and has no effect.

    Order Now 
  • SECOND CAVADEXTRIN® TRIAL (PHASE B)

    12 grams of CAVADEXTRIN® was administered for 17 days over a 30 day period. STUNNING RESULTS! Lipids drop. Liver improves.


    Lipids

    Cholesterol from 10.6 (409) down to 5.5 (212)
    Triglycerides from 20.0 (1771) down to 6.5 (575)
    LDL from 3.7 (143) down to 1.8 (69)

    Liver

    GGT from 102 down to 78
    ALT from 65 down to 48
    AST from 42 down to 31

    Order Now 

Our Future Plans

INCREASE BIOAVAILABILITY OF OUR CAVADEXTRIN® MOLECULE

Design and development of delivery systems to enhance the absorbtion of CAVADEXTRIN® into the blood stream. These include adding absorbtion enhancing excipients.

Order Now

CYCLODEXTRIN DEVELOPMENT AND DISCOVERY

Our researchers are dedicated to the further development of CAVADEXTRIN® and other cyclodextrin derivatives to improve cholesterol transport from the vascular system.

Order Now

EARLY ACCESS INFORMED CONSENT

Heart Disease is an insidious condition that can have tragic consequences with little or no warning. At Cholrem we believe people should be given the opportunity to gain early access to CAVADEXTRIN® based on the science available.

Order Now

How Cholrem was started